NAKAMURA A, NAKAGAWA M, AKASAKA T, SATO K, O'HARA K, SAWAI T; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 246 (abstract no. 77).
Chiba Univ., Chiba, JAPAN
The MICs of various quinolones QNs) and the in vitro combination effect between STFX and FOM against 50 Pseudomonas aeruginosa clinical isolates were investigated. The strains tested were subdivided into two equal groups; those with an MIC of LVFX less than 2 mg/L (LVFX[s]) and those whose MIC was more than 2 mg/L (LVFX[r]). The antibacterial activity of STFX was similar to that of ciprofloxacin (CPFX) against LVFX[s] P. aeruginosa, but was stronger than CPFX and sparfloxacin (SPFX) against the LVFX[r] strains. The combination effect as examined by the checkerboard method was as follows. Synergistic FIC indicates were found in 24 strains (10 LVFX[s] FOM[s], 3 LVFX[s] FOM[r], 3 LVFX[r] FOM[s], and 8 LVFX[r] FOM[r]), and additive FIC indices in 26 strains (11 LVFX[s] FOM[s], 1 LVFX[s] FOM[r], 8 LVFX[r] FOM[s], and 6 LVFX[r] FOM[r]). Neither indifference nor antagonism was found. Correlation between the mechanisms of QN-resistance and their synergistic or additive effects could not be found. One representative strain from each of 8 groups classified by susceptibility and the observed combination effect was tested for additional combination effects using other QNs, such as LVFX, CPFX, and SPFX, with FOM. All FIC indices showed combination effects similar to the case of STFX, though it was clearly shown that STFX was the most effective agent among the QNs used. In conclusion, the combined use of STFX and FOM may be effective against various infections caused by P. aeruginosa.
Publication Types:
Keywords:
- Anti-Bacterial Agents
- Antineoplastic Combined Chemotherapy Protocols
- Ciprofloxacin
- FOM protocol
- Fluoroquinolones
- Fosfomycin
- In Vitro
- Microbial Sensitivity Tests
- Pseudomonas aeruginosa
- Quinolones
- sitafloxacin
- sparfloxacin
Other ID:
UI: 102245312
From Meeting Abstracts